Product Name: Akt3 (132-146)
Product Number: PE-01AWS90
Size: 200 µg      Price:45.00
1 mg      $US90.00
5 mg      211.00
Peptide Name: Akt3 (132-146)

Product Use: The peptide sequence is located just before the kinase catalytic domain.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CEMDASTTHHKRKTMN

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1889.12 Da

Peptide Purity Percent after Synthesis and Purification: >90

Peptide Appearance: White powder

Peptide Form: Solid
Storage Conditions: -20°C

Scientific Background: Akt3 (PKBG, PRKBG) is a protein-serine/threonine kinase of the AGC group and Akt family. Akt3 appears to be an oncoprotein (OP) based on its similarity to Akt1 and Akt2, although it does not display a higher than normal rate of mutation in human tumours. The active form of the protein kinase normally acts to promote tumour cell proliferation. Akt3 has been implicated as a key modulator in several human cancer types, including melanomas, gliomas, ovarian cancer, and breast cancer. Expression levels of Akt3 have been shown to increase throughout the course of melanoma tumour progression, peaking in advanced-stage metastatic melanomas. Mutations in the Akt3 gene have been observed in several melanoma cell lines, including an activating E17K substitution mutation similar to that seen in the Akt1 gene in human colorectal cancers. However, the E17K mutation is relatively rare in Akt3 in human tumours. Moreover, like Akt2, there are no predominent mutations in Akt3 in human cancers, with a relatively dispersed pattern of low level mutations through out the full length of the protein. Along with Akt2, Akt3 is also important in the formation and progression of glioblastomas. In addition, a fusion gene involving Akt3 has been identified in breast cancer tissue samples. The MAGI3/Akt3 fusion gene was recurrently identified in triple-negative breast cancer specimens, which lack estrogen receptors, progesterone receptors, and ERBB2 expression. The fusion gene results in constitutive activation of the Akt3, and suppresses apoptosis and stimulates aberrant cell growth and enhanced survival. Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.